1. To determine the value of using piperacillin/tazobactam in reducing the cases of
extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization
and infection.
2. To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both
pre-and post-intervention in the selected medical centers.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Piperacillin Piperacillin, Tazobactam Drug Combination